ArticleCureus2025
Unmasking Amoebiasis: An Unexpected Cause of Colitis in a Non-endemic Region.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amoebic colitis is a common mimic of inflammatory bowel disease (IBD), primarily encountered in developing countries. We present a case of a 73-year-old British male with no travel history to any amoebic endemic regions, who presented with a three-month history of per rectal (PR) bleeding, diarrhoea, and a positive faecal immunochemical test (FIT). Prior to this, he reported no history of experiencing any gastrointestinal symptoms. Colonoscopy revealed patchy pan-colitis, most marked in the ascending colon, and histology confirmed chronic inflammation. A diagnosis of IBD was made, and the patient was started on corticosteroids and 5-aminosalicylates (5-ASA). He subsequently presented to the emergency department (ED) with worsening symptoms and rising inflammatory markers. Flexible sigmoidoscopy showed progression of inflammation, and despite treatment with intravenous corticosteroids and infliximab, a tumour necrosis factor-alpha (TNF-α) inhibitor, there was no improvement. Cross-sectional imaging performed due to new-onset breathlessness during this admission identified multiple hepatic abscesses and a superior mesenteric vein thrombus. Immunosuppression was stopped, and broad-spectrum antibiotics were initiated. Liver biopsy showed inflammatory cells, but no microorganisms were seen on cultures. Due to treatment-refractory colitis and contraindications to further immunosuppression, the patient underwent a laparoscopic subtotal colectomy with end ileostomy. Histology of the resected bowel was not in keeping with IBD, prompting re-evaluation of the initial biopsies taken from the colonoscopy at first presentation. On re-examination, amoebic-like trophozoites were seen, and the diagnosis of amoebic colitis was confirmed following review by a tertiary centre for specialist infectious disease and gastrointestinal pathology. This case highlights the need for a broad differential when managing treatment-refractory colitis, particularly in non-endemic regions, where the index of suspicion for amoebic colitis is low, and the risk of misdiagnosis is high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.